NASDAQ
HZNP

Horizon Pharma PLC

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Horizon Pharma PLC Stock Price

Vitals

Today's Low:
$115.14
Today's High:
$115.48
Open Price:
$115.44
52W Low:
$60.0303
52W High:
$115.7
Prev. Close:
$114.75
Volume:
5411414

Company Statistics

Market Cap.:
$26.28 billion
Book Value:
23.198
Revenue TTM:
$3.64 billion
Operating Margin TTM:
17.68%
Gross Profit TTM:
$2.80 billion
Profit Margin:
12.02%
Return on Assets TTM:
4.44%
Return on Equity TTM:
8.54%

Company Profile

Horizon Pharma PLC had its IPO on 2011-07-28 under the ticker symbol HZNP.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Horizon Pharma PLC has a staff strength of 2,190 employees.

Stock update

Shares of Horizon Pharma PLC opened at $115.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $115.14 - $115.48, and closed at $115.37.

This is a +0.54% increase from the previous day's closing price.

A total volume of 5,411,414 shares were traded at the close of the day’s session.

In the last one week, shares of Horizon Pharma PLC have increased by +0.06%.

Horizon Pharma PLC's Key Ratios

Horizon Pharma PLC has a market cap of $26.28 billion, indicating a price to book ratio of 5.1009 and a price to sales ratio of 6.9288.

In the last 12-months Horizon Pharma PLC’s revenue was $3.64 billion with a gross profit of $2.80 billion and an EBITDA of $669.21 million. The EBITDA ratio measures Horizon Pharma PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Horizon Pharma PLC’s operating margin was 17.68% while its return on assets stood at 4.44% with a return of equity of 8.54%.

In Q2, Horizon Pharma PLC’s quarterly earnings growth was a positive 107.7% while revenue growth was a positive 7.8%.

Horizon Pharma PLC’s PE and PEG Ratio

Forward PE
21.7391
Trailing PE
61.0372
PEG
1

Its diluted EPS in the last 12-months stands at $1.88 per share while it has a forward price to earnings multiple of 21.7391 and a PEG multiple of 1. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Horizon Pharma PLC’s profitability.

Horizon Pharma PLC stock is trading at a EV to sales ratio of 7.0474 and a EV to EBITDA ratio of 24.6323. Its price to sales ratio in the trailing 12-months stood at 6.9288.

Horizon Pharma PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$9.30 billion
Total Liabilities
$917.68 million
Operating Cash Flow
$-20026000.00
Capital Expenditure
$18.47 million
Dividend Payout Ratio
0%

Horizon Pharma PLC ended 2024 with $9.30 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $9.30 billion while shareholder equity stood at $5.31 billion.

Horizon Pharma PLC ended 2024 with $264.82 million in deferred long-term liabilities, $917.68 million in other current liabilities, 23000.00 in common stock, $771.76 million in retained earnings and $1.01 billion in goodwill. Its cash balance stood at $2.46 billion and cash and short-term investments were $2.46 billion. The company’s total short-term debt was $16,000,000 while long-term debt stood at $2.54 billion.

Horizon Pharma PLC’s total current assets stands at $3.92 billion while long-term investments were $0 and short-term investments were $31.89 million. Its net receivables were $717.42 million compared to accounts payable of $85.54 million and inventory worth $170.33 million.

In 2024, Horizon Pharma PLC's operating cash flow was $-20026000.00 while its capital expenditure stood at $18.47 million.

Comparatively, Horizon Pharma PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$115.37
52-Week High
$115.7
52-Week Low
$60.0303
Analyst Target Price
$116.5

Horizon Pharma PLC stock is currently trading at $115.37 per share. It touched a 52-week high of $115.7 and a 52-week low of $115.7. Analysts tracking the stock have a 12-month average target price of $116.5.

Its 50-day moving average was $105.34 and 200-day moving average was $106.75 The short ratio stood at 4.49 indicating a short percent outstanding of 0%.

Around 118.4% of the company’s stock are held by insiders while 10085.2% are held by institutions.

Frequently Asked Questions About Horizon Pharma PLC

The stock symbol (also called stock or share ticker) of Horizon Pharma PLC is HZNP

The IPO of Horizon Pharma PLC took place on 2011-07-28

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$3.6
0
0%
$3.66
-0.08
-2.14%
$0.17
0.01
+6.96%
$721.25
-18.9
-2.55%
$164.25
-6.2
-3.64%
Scworx Corp (WORX)
$0.19
-0
-1.54%
$33.4
-3.05
-8.37%
$0.26
0.01
+2.4%
$665.55
-59.95
-8.26%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Address

70 St. Stephen?s Green, Dublin, Ireland, 2